DHR has been the topic of a number of other reports. Cowen reaffirmed a buy rating and issued a $90.00 price objective on shares of Danaher in a research note on Wednesday, October 4th. Morgan Stanley reaffirmed an overweight rating and issued a $95.00 price objective (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. Zacks Investment Research raised Danaher from a hold rating to a buy rating and set a $97.00 price objective on the stock in a research note on Thursday, October 5th. Credit Suisse Group reaffirmed a hold rating and issued a $99.00 price objective on shares of Danaher in a research note on Tuesday, December 19th. Finally, Robert W. Baird lifted their price objective on Danaher from $87.00 to $97.00 and gave the stock an outperform rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $94.91.
Danaher (DHR) traded up $0.45 during trading on Wednesday, hitting $94.12. The company had a trading volume of 2,081,056 shares, compared to its average volume of 2,741,167. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The firm has a market capitalization of $65,470.00, a price-to-earnings ratio of 28.01, a P/E/G ratio of 2.02 and a beta of 1.03. Danaher has a one year low of $78.97 and a one year high of $95.16.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. Danaher’s payout ratio is currently 16.67%.
In other news, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares in the company, valued at $9,501,679.22. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GQG Partners LLC bought a new stake in shares of Danaher during the second quarter valued at approximately $101,000. Zions Bancorporation increased its holdings in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after acquiring an additional 667 shares in the last quarter. Patten Group Inc. increased its holdings in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after acquiring an additional 3,497 shares in the last quarter. Monetary Management Group Inc. increased its holdings in shares of Danaher by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after acquiring an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in shares of Danaher by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3126188/danaher-dhr-coverage-initiated-by-analysts-at-evercore-isi.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.